The factor V G1691A (factor V Leiden, FVL) and factor II G20210A gain-of-function
mutations are the most frequent forms of inherited thrombophilia [
1
,
2
]. However, considering their prevalence in the healthy Caucasian population (3–10%
depending on the region), the increase in thromboembolic risk is merely 3–5 times
that of non-carriers and the large majority of carriers will not suffer any thromboembolic
event [
1
,
3
]. Therefore, screening for the presence of FVL and G20210A is controversial, particularly
in patients without a strong personal or familial history of thrombosis and those
in whom the results would not have therapeutic implications.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Factor V Leiden thrombophilia.Genet Med. 2011; 13: 1-16https://doi.org/10.1097/GIM.0b013e3181faa0f2
- The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population.Thromb Haemost. 1998; 80: 366-369
- Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms.J Thromb Haemost. 2010; 8: 2443-2449https://doi.org/10.1111/j.1538-7836.2010.04038.x
- Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest. 2016; 149: 315-352
- Inherited thrombophilia: a double-edged sword.Hematology Am Soc Hematol Educ Program. 2016; 2016: 1-9
- Increased risk for venous thrombosis in carriers of the prothrombin G-->A20210 gene variant.Ann Intern Med. 1998; 129: 89-93
- Geographic distribution of the 20210 G to A prothrombin variant.Thromb Haemost. 1998; 79: 706-708
- Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C).Blood. 1997; 89: 1963-1967
- Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest. 2016; 149: 315-352https://doi.org/10.1016/j.chest.2015.11.026
- Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism.Curr Opin Hematol. 2012; 19: 363-370https://doi.org/10.1097/MOH.0b013e328356745b
Article info
Publication history
Published online: February 24, 2017
Accepted:
February 21,
2017
Received:
February 16,
2017
Identification
Copyright
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
